Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on February 9, 2010, at a price of £12.24 per share through the Company's Share Reward Plan. Each individual acquired 11 shares via the partnership element (personal contribution) and 11 shares via the matching element (Company contribution). No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.24 per Ordinary share on February 9, 2010.
- Confirm the total number of shares acquired by each listed director (22 shares per person: 11 personal, 11 company-matched).
- Review the full list of participating directors: A P Witty, J S Heslop, S M Bicknell, E J Gray, S A Hussain, D Learmouth, D S Redfern, and C Thomas.
- Note that this filing does not replace or supplement quarterly or annual financial reports.